Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:DRRX NASDAQ:GNTA NASDAQ:IRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$11.22-0.9%$9.32$5.01▼$18.70$67.48M0.2667,242 shs19,891 shsDRRXDURECT$1.85-0.5%$0.75$0.48▼$2.64$57.74M0.832.82 million shs438,678 shsGNTAGenenta Science$3.78+2.2%$3.80$2.74▼$7.28$67.67M0.625,758 shs1,736 shsIRDOpus Genetics$1.11+2.8%$1.05$0.65▼$1.86$64.43M0.01225,714 shs76,947 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-0.88%-4.35%+40.07%+54.55%+37.33%DRRXDURECT-0.54%-1.60%+177.49%+217.87%+36.03%GNTAGenenta Science+0.40%-0.26%-2.30%-6.23%-14.48%IRDOpus Genetics+2.78%-2.63%+11.00%+8.82%+110,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.8342 of 5 stars3.41.00.04.70.63.30.6DRRXDURECT1.0482 of 5 stars0.03.00.04.42.40.00.0GNTAGenenta Science2.3427 of 5 stars3.53.00.00.02.41.70.0IRDOpus Genetics1.1861 of 5 stars3.50.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.83Moderate Buy$20.0078.25% UpsideDRRXDURECT 2.00HoldN/AN/AGNTAGenenta Science 3.00Buy$25.00561.38% UpsideIRDOpus Genetics 3.00Buy$7.33560.66% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, IRD, GNTA, and ATRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025DRRXDURECTNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.52N/AN/A($16.89) per share-0.66DRRXDURECT$2.03M28.29N/AN/A$0.29 per share6.38GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/AIRDOpus Genetics$10.99M6.03N/AN/A$0.21 per share5.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$85.40M-$3.72N/AN/AN/A-7.83%N/A-14.51%8/11/2025 (Estimated)DRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/AIRDOpus Genetics-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)Latest DRRX, IRD, GNTA, and ATRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DRRXDURECT-$0.13N/AN/AN/A$0.32 millionN/A8/12/2025N/AIRDOpus Genetics-$0.25N/AN/AN/A$4.27 millionN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32N/AN/AN/A$4.23 millionN/A5/15/2025Q1 2025ATRAAtara Biotherapeutics-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.570.57DRRXDURECTN/A1.231.22GNTAGenenta ScienceN/A6.896.89IRDOpus GeneticsN/A1.981.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%DRRXDURECT28.03%GNTAGenenta Science15.13%IRDOpus Genetics14.97%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.00%DRRXDURECT3.20%GNTAGenenta Science28.99%IRDOpus Genetics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.96 million5.72 millionOptionableDRRXDURECT8031.04 million30.05 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableIRDOpus Genetics1459.66 million55.72 millionN/ADRRX, IRD, GNTA, and ATRA HeadlinesRecent News About These CompaniesOpus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 5 at 8:00 AM | globenewswire.comOpus Genetics & Global RDH12 Alliance partner to advance RDH12 gene therapy for inherited childhood blindnessJuly 28, 2025 | pharmabiz.comPOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 24, 2025 | finance.yahoo.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Raised to "Hold" at Wall Street ZenJuly 12, 2025 | marketbeat.comOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comOpus Genetics, Inc. (IRD) Income Statement - Yahoo FinanceJune 30, 2025 | finance.yahoo.comOpus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJune 26, 2025 | globenewswire.comOpus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK ProgramJune 23, 2025 | globenewswire.comPhentolamine Eye Drops Improve Night Driving Post-Refractive Surgery in Phase 3 trialJune 20, 2025 | medicaldialogues.inMOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...June 4, 2025 | seekingalpha.comIRD Opus Genetics, Inc.June 3, 2025 | seekingalpha.comOpus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%June 2, 2025 | ophthalmologytimes.comOOpus Genetics Shares Rise After Positive Trial Results for Eye TreatmentJune 2, 2025 | marketwatch.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2, 2025 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 18, 2025 | finance.yahoo.comOpus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comOpus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025May 13, 2025 | nasdaq.comOpus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in MayMay 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?This Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025View This Drone Stock Is on Sale Despite Big Army ContractCould Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpBy Jordan Chussler | July 7, 2025View Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpDRRX, IRD, GNTA, and ATRA Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$11.22 -0.10 (-0.88%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$11.42 +0.21 (+1.83%) As of 08/5/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.DURECT NASDAQ:DRRX$1.85 -0.01 (-0.54%) As of 08/5/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Genenta Science NASDAQ:GNTA$3.78 +0.08 (+2.16%) As of 08/5/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Opus Genetics NASDAQ:IRD$1.11 +0.03 (+2.78%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.90%) As of 08/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
